Literature DB >> 31171596

A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans.

Mouna Tahmi1, Wassim Bou-Zeid2, Qolamreza R Razlighi2,3.   

Abstract

Spatial heterogeneity in the accumulation of amyloid-β plaques throughout the brain during asymptomatic as well as clinical stages of Alzheimer disease calls for precise localization and quantification of this protein using PET imaging. To address this need, we have developed and evaluated a technique that quantifies the extent of amyloid-β pathology on a millimeter-by-millimeter scale in the brain with unprecedented precision using data from PET scans.
Methods: An intermodal and intrasubject registration with normalized mutual information as the cost function was used to transform all FreeSurfer neuroanatomic labels into PET image space, which were subsequently used to compute regional SUV ratio (SUVR). We have evaluated our technique using postmortem histopathologic staining data from 52 older participants as the standard-of-truth measurement.
Results: Our method resulted in consistently and significantly higher SUVRs in comparison to the conventional method in almost all regions of interest. A 2-way ANOVA revealed a significant main effect of method as well as a significant interaction effect of method on the relationship between computed SUVR and histopathologic staining score.
Conclusion: These findings suggest that processing the amyloid-β PET data in subjects' native space can improve the accuracy of the computed SUVRs, as they are more closely associated with the histopathologic staining data than are the results of the conventional approach.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-florbetaben PET; Alzheimer disease; FreeSurfer; amyloid-β; spatial normalization

Year:  2019        PMID: 31171596      PMCID: PMC6894379          DOI: 10.2967/jnumed.119.228510

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 2.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Authors:  Mark E Schmidt; Ping Chiao; Gregory Klein; Dawn Matthews; Lennart Thurfjell; Patricia E Cole; Richard Margolin; Susan Landau; Norman L Foster; N Scott Mason; Susan De Santi; Joyce Suhy; Robert A Koeppe; William Jagust
Journal:  Alzheimers Dement       Date:  2014-11-24       Impact factor: 21.566

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Shiaw-Pyng Wey; Mei-Ping Kung; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-15       Impact factor: 9.236

5.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Authors:  Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer
Journal:  Alzheimers Dement       Date:  2015-03-28       Impact factor: 21.566

6.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Authors:  Adam S Fleisher; Kewei Chen; Xiaofen Liu; Auttawut Roontiva; Pradeep Thiyyagura; Napatkamon Ayutyanont; Abhinay D Joshi; Christopher M Clark; Mark A Mintun; Michael J Pontecorvo; P Murali Doraiswamy; Keith A Johnson; Daniel M Skovronsky; Eric M Reiman
Journal:  Arch Neurol       Date:  2011-07-11

Review 7.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  β-Amyloid Deposition Is Associated with Decreased Right Prefrontal Activation during Task Switching among Cognitively Normal Elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Yaakov Stern
Journal:  J Neurosci       Date:  2016-02-10       Impact factor: 6.167

Review 9.  Beta-amyloid imaging with florbetaben.

Authors:  Osama Sabri; John Seibyl; Christopher Rowe; Henryk Barthel
Journal:  Clin Transl Imaging       Date:  2015-02-12

10.  Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.

Authors:  Benjamin M Doherty; Stephanie A Schultz; Jennifer M Oh; Rebecca L Koscik; N Maritza Dowling; Todd E Barnhart; Dhanabalan Murali; Catherine L Gallagher; Cynthia M Carlsson; Barbara B Bendlin; Asenath LaRue; Bruce P Hermann; Howard A Rowley; Sanjay Asthana; Mark A Sager; Brad T Christian; Sterling C Johnson; Ozioma C Okonkwo
Journal:  Alzheimers Dement (Amst)       Date:  2015-06-01
View more
  6 in total

1.  Sex Differences in in vivo Alzheimer's Disease Neuropathology in Late Middle-Aged Hispanics.

Authors:  José A Luchsinger; Priya Palta; Brady Rippon; Luisa Soto; Fernando Ceballos; Michelle Pardo; Krystal Laing; Kay Igwe; Aubrey Johnson; Zeljko Tomljanovic; Hengda He; Christiane Reitz; William Kreisl; Qolamreza Razlighi; Jeanne Teresi; Herman Moreno; Adam M Brickman
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  The Laterality of Early Age-Related Hearing Loss and Brain β-Amyloid.

Authors:  Alexandria L Irace; Brady Q Rippon; Adam M Brickman; José A Luchsinger; Justin S Golub
Journal:  Otol Neurotol       Date:  2022-03-01       Impact factor: 2.311

3.  Pre-Diabetes, but not Type 2 Diabetes, Is Related to Brain Amyloid in Late Middle-Age.

Authors:  José A Luchsinger; Priya Palta; Brady Rippon; Greysi Sherwood; Luisa Soto; Fernando Ceballos; Krystal Laing; Kay Igwe; Hengda He; Qolamreza Razlighi; Jeanne Teresi; Herman Moreno; Adam M Brickman
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

4.  Apolipoprotein E genotype and in vivo amyloid burden in middle-aged Hispanics.

Authors:  Priya Palta; Brady Rippon; Christiane Reitz; Hengda He; Greysi Sherwood; Fernando Ceballos; Jeanne Teresi; Qolamreza Razlighi; Herman Moreno; Adam M Brickman; José A Luchsinger
Journal:  Neurology       Date:  2020-08-26       Impact factor: 9.910

5.  Metabolic syndrome and its components in relation to in vivo brain amyloid and neurodegeneration in late middle age.

Authors:  Priya Palta; Brady Rippon; Mouna Tahmi; Greysi Sherwood; Luisa Soto; Fernando Ceballos; Krystal Laing; Hengda He; Christiane Reitz; Qolamreza Razlighi; Jeanne A Teresi; Herman Moreno; Adam M Brickman; José A Luchsinger
Journal:  Neurobiol Aging       Date:  2020-10-14       Impact factor: 4.673

6.  Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults.

Authors:  Priya Palta; Brady Rippon; Mouna Tahmi; Michelle Pardo; Aubrey Johnson; Zeljko Tomljanovic; Hengda He; Krystal K Laing; Qolamreza R Razlighi; Jeanne A Teresi; Herman Moreno; Adam M Brickman; William C Kreisl; José A Luchsinger
Journal:  Neurobiol Aging       Date:  2021-03-23       Impact factor: 5.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.